Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4202 Target Snapshot

STE20-like serine/threonine-protein kinase · SINGLE PROTEIN · Homo sapiens

1,458Compounds
275Assays
25Approved Drugs
1,132.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9H2G2. Use UniProt Q9H2G2 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9H2G2 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats STE20-like serine/threonine-protein kinase as ChEMBL target CHEMBL4202, mapped to UniProt Q9H2G2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
STE20-like serine/threonine-protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4202
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9H2G2
STE20-like serine/threonine-protein kinase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether STE20-like serine/threonine-protein kinase is the right protein anchor across sources, using UniProt Q9H2G2 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSTE20-like serine/threonine-protein kinase
UniProt AccessionQ9H2G2
Component TypeProtein
Sequence Length1235 aa

STE20-like serine/threonine-protein kinase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as STE20-like serine/threonine-protein kinase, mapped to UniProt Q9H2G2. Sequence length is 1235 aa.

Mapped IDQ9H2G2
Review nameSTE20-like serine/threonine-protein kinase
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

25
Approved
18
Phase III
32
Phase II
19
Phase I
Assay Mix

Activity Type Distribution

IC5037.0
KI700.0
KD395.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 10.7 Kd 0.02 Preclinical
CHEMBL1230609 8.52 Kd 3.0 Clinical
CHEMBL4875188 8.43 Ki 3.7 Preclinical
CHEMBL4878325 8.41 Ki 3.9 Preclinical
CHEMBL288441 8.33 Kd 4.7 Approved
CHEMBL1974328 8.3 Ki 5.012 Preclinical
CHEMBL509032 8.3 Ki 5.012 Preclinical
CHEMBL4465866 8.3 Kd 5.0 Preclinical
CHEMBL4877889 8.22 Ki 6.0 Preclinical
CHEMBL4576489 8.22 Kd 6.0 Preclinical
Distribution

pChEMBL Value Distribution

95
5.0
116
5.5
119
6.0
75
6.5
69
7.0
47
7.5
22
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

ENTRECTINIB
CHEMBL1983268
Approved 2019
FEDRATINIB
CHEMBL1287853
Approved 2019
GILTERITINIB
CHEMBL3301622
Approved 2018
NERATINIB
CHEMBL180022
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
AXITINIB
CHEMBL1289926
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
VANDETANIB
CHEMBL24828
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
DASATINIB
CHEMBL5416410
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
ERLOTINIB
CHEMBL553
Approved 2004
GEFITINIB
CHEMBL939
Approved 2003
Assay Landscape

Assay Landscape

275
Total Assays
300
Tested Compounds
2
Assay Types
Binding — 274 assays, 208 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 177 147 6.8
assay format 34 5 7.0
subcellular format 34 50 5.7
cell-based format 29 6 6.3
Functional — 1 assays, 300 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 300 6.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine